Hao Zhang1, Lingli Sun2, Huaiming Wang3, Huan Cai4, Guozhong Niu5, Yongjie Bai6, Yun Zhang4, Dong Yang3, Mengmeng Gu7, Pengfei Xu2, Xinying Fan2, Xinfeng Liu8, Gelin Xu9. 1. Department of Neurology, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, China; Department of Neurology, The First People's Hospital of Hangzhou, Nanjing Medical University, Hangzhou, Zhejiang 310006, China. 2. Department of Neurology, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, China. 3. Department of Neurology, Jinling Hospital, Second Military Medical University, Nanjing, Jiangsu 210002, China. 4. Department of Neurology, Jinling Hospital, Southern Medical University, Nanjing, Jiangsu 210002, China. 5. Department of Neurology, The First People's Hospital of Hangzhou, Nanjing Medical University, Hangzhou, Zhejiang 310006, China. 6. Department of Neurology, Jinling Hospital, Nanjing Medical University, Nanjing, Jiangsu 210002, China; Department of Neurology, Affiliated Hospital 1, Henan University of Science & Technology, Luoyang 471000, China. 7. Department of Neurology, Jinling Hospital, Nanjing Medical University, Nanjing, Jiangsu 210002, China. 8. Department of Neurology, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, China. Electronic address: xfliu@vip.163.com. 9. Department of Neurology, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, China. Electronic address: gelinxu@nju.edu.cn.
Abstract
BACKGROUND: The variant rs9943582 of APLNR (apelin receptor) was identified by a large-scale study to be associated with an increased risk of ischemic stroke in a Japanese population. We conducted this study to investigate the association between the variant and age of onset and clinical outcomes of ischemic stroke in a Chinese population. METHODS: Improved multiple ligase detection reaction was used to genotype the variant. We compared the mean age at ischemic stroke onset with one-way ANOVA. The Kaplan-Meier method, log-rank test, and Cox proportional hazards regression models were performed to analyze the association between the variant and clinical outcomes (recurrence and death). RESULTS: A total of 916 ischemic stroke patients were recruited for the study. For age at ischemic stroke onset, no significant association was identified with the variant in any genetic model. In addition, the variant was not strongly associated with recurrence and death risk of ischemic stroke, as shown by the results. CONCLUSIONS: The findings indicated that the variant rs9943582 was not associated with age at onset and clinical outcomes of ischemic stroke. However, evidence from well-designed studies with larger and in different ethnic populations are warranted to further explore the effects of APLNR on the ischemic stroke onset and clinical outcomes.
BACKGROUND: The variant rs9943582 of APLNR (apelin receptor) was identified by a large-scale study to be associated with an increased risk of ischemic stroke in a Japanese population. We conducted this study to investigate the association between the variant and age of onset and clinical outcomes of ischemic stroke in a Chinese population. METHODS: Improved multiple ligase detection reaction was used to genotype the variant. We compared the mean age at ischemic stroke onset with one-way ANOVA. The Kaplan-Meier method, log-rank test, and Cox proportional hazards regression models were performed to analyze the association between the variant and clinical outcomes (recurrence and death). RESULTS: A total of 916 ischemic strokepatients were recruited for the study. For age at ischemic stroke onset, no significant association was identified with the variant in any genetic model. In addition, the variant was not strongly associated with recurrence and death risk of ischemic stroke, as shown by the results. CONCLUSIONS: The findings indicated that the variant rs9943582 was not associated with age at onset and clinical outcomes of ischemic stroke. However, evidence from well-designed studies with larger and in different ethnic populations are warranted to further explore the effects of APLNR on the ischemic stroke onset and clinical outcomes.
Authors: Cai Read; Duuamene Nyimanu; Thomas L Williams; David J Huggins; Petra Sulentic; Robyn G C Macrae; Peiran Yang; Robert C Glen; Janet J Maguire; Anthony P Davenport Journal: Pharmacol Rev Date: 2019-10 Impact factor: 25.468